First National Advisers’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.53M Sell
15,261
-1,276
-8% -$437K 0.78% 26
2026
Q1
$5.82M Sell
16,537
-3,852
-19% -$1.37M 0.85% 23
2025
Q4
$6.67M Sell
20,389
-1,342
-6% -$426K 0.92% 20
2025
Q3
$6.13M Buy
21,731
+910
+4% +$264K 0.83% 19
2025
Q2
$5.81M Buy
20,821
+232
+1% +$65.7K 0.85% 19
2025
Q1
$6.41M Buy
20,589
+2,256
+12% +$666K 1.03% 16
2024
Q4
$4.78M Buy
18,333
+288
+2% +$85.4K 0.77% 27
2024
Q3
$5.81M Buy
18,045
+1,052
+6% +$344K 0.93% 20
2024
Q2
$5.31M Buy
16,993
+5,914
+53% +$1.74M 0.97% 19
2024
Q1
$3.11M Buy
11,079
+1,625
+17% +$475K 0.7% 41
2023
Q4
$2.72M Buy
9,454
+4,965
+111% +$1.35M 0.78% 35
2023
Q3
$1.21M Buy
+4,489
New +$1.12M 0.54% 65
2023
Q2
Sell
-837
Closed -$202K 116
2023
Q1
$202K Sell
837
-160
-16% -$39.3K 0.23% 107
2022
Q4
$262K Buy
997
+118
+13% +$31.6K 0.34% 94
2022
Q3
$198K Buy
+879
New +$213K 0.29% 96

Other funds holding AMGN

First National Advisers's AMGN Position: Q2 2026 in Review

First National Advisers reduced its Amgen (AMGN) stake by 7.7% in Q2 2026, selling an estimated $437K and leaving 15,261 shares worth $5.53M. The position accounts for 0.78% of the portfolio, ranked #26.

First National Advisers first reported a position in AMGN in Q3 2022 and has held it in 15 quarters since. The position peaked at $6.67M in Q4 2025. 1,264 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • First National Advisers held 15,261 shares of Amgen worth $5.53M as of Q2 2026.
  • First National Advisers sold 1,276 Amgen shares in Q2 2026, an estimated $437K.
  • Amgen made up 0.78% of First National Advisers's portfolio in Q2 2026, its #26 holding.
  • First National Advisers first reported a position in Amgen in Q3 2022 and has held it in 15 quarters since.
  • First National Advisers's Amgen position peaked at $6.67M in Q4 2025.
  • 1,264 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on First National Advisers's 13F filing for Q2 2026, filed 21 Jul 2026.